For instance, we were unable to look at the testing rates and associated survival for Asian patients who have a markedly higher rate of EGFR mutations than White patients, approximately 50% vs. 20%, respectively, in adenocarcinoma cases [33]. This evidence concerns the gene EGFR and adenocarcinoma.